___

• Akhand SS, Liu Z, Purdy SC, Abdullah A, Lin H et al. (2020). Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade. Cancer Immunol Research 8: 1542-1553.
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
• Brown JL, Russell PJ, Philips J, Wotherspoon J, Raghavan D (1990). Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity. British Journal of Cancer 61: 369-376.
• Cancer Genome Atlas Research N (2014). Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507: 315-322.
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2: 401-404.
• Chehrazi-Raffle A, Dorff TB, Pal SK, Lyou Y (2021). Wnt/betaCatenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. Cancers 13: (4): 889. doi: 10.3390/cancers13040889
• Cheng T, Roth B, Choi W, Black PC, Dinney C et al. (2013). Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PloS One 8: e57284.
• Choi W, Porten S, Kim S, Willis D, Plimack ER et al. (2014). Identification of distinct basal and luminal subtypes of muscleinvasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25: 152-165.
• Cormio L, Sanguedolce F, Cormio A, Massenio P, Pedicillo MC et al. (2017). Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer. Oncotarget 8: 25433-25441.
• Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodriguez-Santiago B, Mendez-Pertuz M et al. (2015). The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. BMC Genomics 16: 403.
• Eray A, Guneri PY, Yilmaz GO, Karakulah G, Erkek-Ozhan S (2020). Analysis of open chromatin regions in bladder cancer links beta-catenin mutations and Wnt signaling with neuronal subtype of bladder cancer. Scientific Reports 10: 18667.
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling 6 (269): pl1. doi: 10.1126/scisignal.2004088
• Gatta LB, Melocchi L, Bugatti M, Missale F, Lonardi S et al. (2019). Hyper-Activation of STAT3 Sustains Progression of NonPapillary Basal-Type Bladder Cancer via FOSL1 Regulome. Cancers 11 (9): 1-25. doi: 10.3390/cancers11091219
• Ghervan L, Zaharie A, Ene B, Elec FI (2017). Small-cell carcinoma of the urinary bladder: where do we stand? Clujul Medical 90: 13-17.
• Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S et al. (2016). Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell 30: 27-42.
• Ho PL, Lay EJ, Jian W, Parra D, Chan KS (2012). Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer. Cancer Research 72: 3135-3142.
• Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ et al. (2014). Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 5: 1635-1645.
• Kamburov A, Pentchev K, Galicka H, Wierling C, Lehrach H et al. (2011). ConsensusPathDB: toward a more complete picture of cell biology. Nucleic Acids Research 39: D712-717.
• Kamburov A, Wierling C, Lehrach H, Herwig R (2009). ConsensusPathDB--a database for integrating human functional interaction networks. Nucleic Acids Research 37: D623-628.
• Kamoun A, de Reynies A, Allory Y, Sjodahl G, Robertson AG et al. (2020). A Consensus Molecular Classification of Muscleinvasive Bladder Cancer. European Urology 77: 420-433.
• Kolde R (2019). pheatmap: Pretty Heatmaps. Krishnamurthy N, Kurzrock R (2018). Targeting the Wnt/betacatenin pathway in cancer: Update on effectors and inhibitors. Cancer Treatment Reviews 62: 50-60.
• Larsen JE, Nathan V, Osborne JK, Farrow RK, Deb D et al. (2016). ZEB1 drives epithelial-to-mesenchymal transition in lung cancer. Journal of Clinical Investigation 126: 3219-3235.
• Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS et al. (2021). An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nature Communications 12: 2301.
• Makridakis M, Gagos S, Petrolekas A, Roubelakis MG, Bitsika V et al. (2009). Chromosomal and proteome analysis of a new T24- based cell line model for aggressive bladder cancer. Proteomics 9: 287-298.
• Moustakas G, Kampantais S, Nikolaidou A, Vakalopoulos I, Tzioufa V et al. (2020). HER-2 overexpression is a negative predictive factor for recurrence in patients with non-muscle-invasive bladder cancer on intravesical therapy. Journal of International Medical Research 48 (1): 300060519895847.
• Nickerson ML, Witte N, Im KM, Turan S, Owens C et al. (2017). Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene 36: 35-46.
• Parker TW, Neufeld KL (2020). APC controls Wnt-induced beta-catenin destruction complex recruitment in human colonocytes. Scientific Reports 10: 2957.
• Piantino CB, Sousa-Canavez JM, Srougi V, Salvadori F, Kato R et al. (2010). Establishment and characterization of human bladder cancer cell lines BexBra1, BexBra2, and BexBra4. In Vitro Cellular and Developmental Biology. Animal 46: 131-139.
• Pinto-Leite R, Carreira I, Melo J, Ferreira SI, Ribeiro I et al. (2014). Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer. Tumour Biology 35: 4599-4617.
• Pluciennik E, Nowakowska M, Pospiech K, Stepien A, Wolkowicz M et al. (2015). The role of WWOX tumor suppressor gene in the regulation of EMT process via regulation of CDH1-ZEB1- VIM expression in endometrial cancer. International Journal of Oncology 46: 2639-2648.
• Rebouissou S, Bernard-Pierrot I, de Reynies A, Lepage ML, Krucker C et al. (2014). EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basallike phenotype. Science Translational Medicine 6: 244ra291.
• Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA et al. (2017). FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget 8: 47595-47606.
• Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G et al. (2017). Comprehensive Molecular Characterization of MuscleInvasive Bladder Cancer. Cell 171: 540-556 e525.
• Sikic D, Eckstein M, Wirtz RM, Jarczyk J, Worst TS et al. (2020). FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. Journal of Clinical Medicine 9 (4): 994. doi: 10.3390/ jcm9040994
• Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S et al. (2012). A molecular taxonomy for urothelial carcinoma. Clinical Cancer Research 18: 3377-3386.
• Takeyama Y, Sato M, Horio M, Hase T, Yoshida K et al. (2010). Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. Cancer Letters 296: 216-224.
• Tan TZ, Rouanne M, Tan KT, Huang RY, Thiery JP (2019). Molecular Subtypes of Urothelial Bladder Cancer: Results from a Metacohort Analysis of 2411 Tumors. European Urology 75: 423- 432.
• Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA (2009). Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Research 69: 4613-4620.
• Walter W, Sanchez-Cabo F, Ricote M (2015). GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics 31: 2912-2914.
• Wang Y, Li Q, Wang J, Tong M, Xing H et al. (2019). Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up. Medical Oncology 36: 98.
• Warrick JI, Walter V, Yamashita H, Chung E, Shuman L et al. (2016). FOXA1, GATA3 and PPAR Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines. Scientific Reports 6: 38531.
• Wu S, Du Y, Beckford J, Alachkar H (2018). Upregulation of the EMT marker vimentin is associated with poor clinical outcome in acute myeloid leukemia. Journal of Translational Medicine 16: 170.
• Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S et al. (2020). Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience 23: 101201.
• Zuiverloon TCM, de Jong FC, Costello JC, Theodorescu D (2018). Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines. Bladder Cancer 4: 169-183.